← Silence Therapeutics plc
| Annual Trend | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | TTM | |
|---|---|---|---|---|---|---|---|---|---|
| Cash flows from operating activities: | |||||||||
| Adjustments to reconcile net income to net cash provided by operating activities: | |||||||||
| Net Income From Continuing Operations | ($19.6m) | ($32.5m) | ($39.4m) | ($40.5m) | ($43.3m) | ($45.3m) | ($88.6m) | ($75.0m) | |
| Depreciation | — | — | — | — | — | $336k | $312k | $311k | |
| Amortization | — | — | — | — | — | $257k | $243k | $212k | |
| Depreciation charges | $452k | $476k | $411k | $478k | $462k | — | — | $523k | |
| Amortization charges | $30k | $20k | $16k | $4k | $36k | — | — | — | |
| Depreciation Amortization Depletion | — | — | — | — | — | $593k | $555k | $523k | |
| Deferred Income Tax Expense (Benefit) | — | — | — | — | — | $845k | $11k | $11k | |
| Deferred Tax | — | — | — | — | — | $845k | $11k | $11k | |
| Share-based Payment Arrangement, Noncash Expense | — | — | — | — | — | $16.3m | $8.1m | $7.0m | |
| Adjustments For Share-Based Payments | $584k | $4.4m | $8.6m | $10.3m | $13.1m | — | — | — | |
| Share-based Payment Arrangement, Expense | — | — | — | — | — | $16.3m | $8.1m | $7.0m | |
| Charge for the year in respect of share-based payments | $584k | $4.4m | $8.6m | $10.3m | $13.1m | — | — | — | |
| Goodwill, Impairment Loss | — | — | — | — | — | $0 | $0 | — | |
| Impairment of Intangible Assets (Excluding Goodwill) | — | — | — | — | — | $0 | $0 | — | |
| Changes in operating assets and liabilities: | |||||||||
| Change In Working Capital | — | — | — | — | — | ($33.0m) | $10.2m | ($3.0m) | |
| Increase (Decrease) in Accounts Receivable | — | — | — | — | — | $904k | ($1.0m) | ($4.4m) | |
| (Increase)/decrease in trade and other receivables | ($4k) | ($29.3m) | $27.5m | ($584k) | $314k | — | — | — | |
| Change In Receivables | — | — | — | — | — | ($3.2m) | $5.1m | ($4.4m) | |
| Changes In Account Receivables | — | — | — | — | — | ($904k) | $1.0m | ($4.4m) | |
| Increase in trade and other payables | $3.1m | $1.3m | $2.4m | $1.4m | $44k | — | — | — | |
| Increase in other current assets | ($4k) | ($3.7m) | ($904k) | ($4.2m) | $610k | — | — | — | |
| Change In Other Current Assets | — | — | — | — | — | ($1.3m) | $9.7m | $11.1m | |
| Change In Other Current Liabilities | — | — | — | — | — | ($165k) | ($168k) | ($133k) | |
| Net Cash Provided by (Used in) Operating Activities | $1.7m |
($10.8m)
-723.97%
|
$6.8m
+163.16%
|
($45.5m)
-767.88%
|
($39.4m)
+13.43%
|
($67.6m)
-71.89%
|
($62.3m)
+7.94%
|
($65.6m)
-5.29%
|
|
| Cash flows from investing activities: | |||||||||
| Payments to Acquire Property, Plant, and Equipment | ($9k) | ($511k) | ($1.3m) | ($140k) | ($45k) | $211k | $55k | ($687k) | |
| Proceeds From Sales Of Property Plant And Equipment Classified As Investing Activities | — | $3k | — | — | — | — | — | — | |
| Cash, Cash Equivalents, and Short-term Investments | — | — | — | — | — | $147.3m | $85.1m | — | |
| Net cash (outflow)/inflow from investing activities | ($15.0m) | $9.6m | $8.7m | ($16.5m) | $16.4m | — | — | — | |
| Net Cash Provided by (Used in) Investing Activities | — | — | — | — | — | ($22.0m) | ($48.0m) | $6.4m | |
| Cash flows from financing activities: | |||||||||
| Net Issuance Payments Of Debt | — | — | ($285k) | ($230k) | ($222k) | — | — | ($113k) | |
| Net Long Term Debt Issuance | — | — | ($285k) | ($230k) | ($222k) | — | — | ($113k) | |
| Long Term Debt Payments | — | — | ($285k) | ($230k) | ($222k) | — | — | ($113k) | |
| Repayment Of Debt | — | — | ($285k) | ($230k) | ($222k) | — | — | ($113k) | |
| Issuance Of Capital Stock | — | — | — | — | — | $142.1m | $15k | $1k | |
| Proceeds from Issuance of Common Stock | — | — | — | — | — | $142.1m | $15k | $1k | |
| Common Stock Issuance | — | — | — | — | — | $142.1m | $15k | $1k | |
| Net cash inflow from financing activities | $5.3m |
$15.4m
+192.58%
|
$30.7m
+99.06%
|
$43.0m
+40.17%
|
$25.2m
-41.57%
|
— | — | — | |
| Net Cash Provided by (Used in) Financing Activities | — | — | — | — | — | $142.1m |
$15k
-99.99%
|
$1k
-93.33%
|
|
| (Decrease)/increase in cash and cash equivalents | ($8.0m) | $14.3m | $46.2m | ($18.9m) | $2.2m | — | — | — | |
| Beginning Cash Position | — | — | — | — | — | $68.8m | $121.3m | $64.9m | |
| Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents | — | — | — | — | — | $60k | $195k | ($54k) | |
| Effect of exchange rate fluctuations on cash and cash equivalents held | $36k | ($336k) | ($105k) | $228k | ($3.0m) | — | — | — | |
| Effect Of Exchange Rate Changes | — | — | — | — | — | $60k | $195k | ($54k) | |
| Additional Supplementary Disclosures | |||||||||
| Additional Supplementary Disclosures | |||||||||
| Additional Financial Items | |||||||||
| Adjustments For Current Tax Of Prior Period | ($228k) | $42k | ($875k) | $401k | ($15k) | — | — | — | |
| Adjustments For Finance Costs | $163k | $323k | $52k | — | $2.2m | — | — | — | |
| Adjustments For Finance Income | $27k | $129k | $10k | $1.3m | $1.4m | — | — | — | |
| Foreign Currency Transaction Gain (Loss), before Tax | — | — | — | — | — | $646k | ($8.5m) | — | |
| General and Administrative Expense | — | — | $20.0m | $19.6m | $20.6m | $26.9m | $22.3m | — | |
| Goodwill | $7.7m | $8.1m | $7.6m | $8.0m | $7.8m | $9.4m | $10.6m | — | |
| Payments Of Lease Liabilities Classified As Financing Activities | — | $402k | $211k | $190k | $174k | — | — | — | |
| Proceeds From Issuing Shares | $5.3m | $15.8m | $30.9m | $43.2m | $25.3m | — | — | — | |
| Purchase Of Intangible Assets Classified As Investing Activities | — | $3k | $23k | $300k | — | — | — | — | |
| Loss before tax | ($22.9m) | ($36.0m) | ($45.9m) | ($47.4m) | ($50.3m) | — | — | — | |
| Net foreign exchange (gain)/loss | — | $4.9m | $305k | $713k | $2.2m | — | — | — | |
| Finance and other expenses | $163k | $323k | $52k | — | $2.2m | — | — | — | |
| Finance and other income | ($27k) | ($129k) | ($10k) | ($1.3m) | ($1.4m) | — | — | — | |
| (Increase) in R&D tax credit receivable | — | — | — | ($502k) | ($1.8m) | — | — | — | |
| (Decrease)/increase in contract liabilities | $18.0m | $50.4m | $8.4m | ($4.4m) | ($8.3m) | — | — | — | |
| Cash generated/(spent) on operations | ($581k) | ($13.8m) | $2.4m | ($45.5m) | ($45.6m) | — | — | — | |
| R&D tax credits received | $2.3m | $3.0m | $4.4m | $7.8m | $6.9m | — | — | — | |
| Redemption of financial assets at amortized cost - term deposits | ($15.0m) | $10.0m | $10.0m | — | $36.2m | — | — | — | |
| Purchase of financial assets at amortized cost | — | — | — | ($16.1m) | ($20.7m) | — | — | — | |
| Interest received | ($6k) | $129k | $10k | $23k | $958k | — | — | $11k | |
| Purchase of intangible assets | — | ($3k) | ($23k) | ($300k) | — | — | — | — | |
| Repayment of lease liabilities | — | ($402k) | ($211k) | ($190k) | ($174k) | — | — | — | |
| Proceeds from issue of share capital | $5.3m | $15.8m | $30.9m | $43.2m | $25.3m | — | — | — | |
| Cash Flow From Continuing Financing Activities | — | — | — | — | — | $142.1m | $15k | $1k | |
| Cash Flow From Continuing Investing Activities | — | — | — | — | — | ($22.0m) | ($48.0m) | $6.4m | |
| Change In Other Working Capital | — | — | — | — | — | ($28.8m) | ($334k) | ($666k) | |
| Change In Payable | — | — | — | — | — | $499k | ($4.1m) | ($8.9m) | |
| Changes In Cash | — | — | — | — | — | $52.5m | ($110.2m) | ($59.2m) | |
| End Cash Position | — | — | — | — | — | $121.3m | $11.3m | $5.7m | |
| Financing Cash Flow | — | — | — | — | — | $142.1m |
$15k
-99.99%
|
$1k
-93.33%
|
|
| Free Cash Flow | — | — | — | — | — | ($67.9m) | ($62.3m) | ($65.6m) | |
| Gain Loss On Sale Of PPE | — | — | $0 | $0 | — | — | — | $0 | |
| Interest Received CFI | — | — | $13k | $28k | $1.2m | — | — | $11k | |
| Investing Cash Flow | — | — | — | — | — | ($22.0m) | ($48.0m) | $6.4m | |
| Net Foreign Currency Exchange Gain Loss | — | — | — | — | — | ($2.6m) | $11.0m | $8.0m | |
| Net Intangibles Purchase And Sale | — | — | ($31k) | — | $0 | $0 | — | $0 | |
| Net PPE Purchase And Sale | — | — | — | — | — | ($211k) | ($55k) | ($51k) | |
| Operating Gains Losses | — | — | — | — | — | ($2.6m) | $11.0m | $8.0m | |
| Other Non Cash Items | — | — | — | — | — | ($4.5m) | ($3.5m) | — | |
| Purchase Of Intangibles | — | — | ($31k) | — | $0 | $0 | — | $0 | |
| Purchase Of PPE | — | — | — | — | — | ($211k) | ($55k) | ($687k) | |
| Stock Based Compensation | — | — | — | — | — | $16.3m | $8.1m | $7.0m | |
| Net Investment Purchase And Sale | — | — | — | — | — | ($21.8m) | ($47.9m) | $6.4m | |
| Purchase Of Investment | — | — | — | — | — | ($139.2m) | ($166.4m) | ($160.8m) | |
| Sale Of Investment | — | — | — | $0 | — | $117.4m | $118.5m | $167.2m | |
| Cash and cash equivalents at start of year | $13.5m | $27.4m | $73.5m | $54.8m | $54.0m | — | — | — | |
| Supplemental disclosure of cash flow information: | |||||||||
| Change In Cash Supplemental As Reported | — | — | — | — | — | $52.5m | ($110.2m) | — | |
| Income Taxes Paid, Net | — | — | — | — | ($642k) | ($433k) | $637k | — |